– Reuters
Cocrystal Pharma Selects CDI-988 For Clinical Development As An Oral Treatment For COVID-19
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an